REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today announced that management will present at the following investor conferences:
Wells Fargo Healthcare Conference
Format: Fireside Chat and 1×1 meetings
Date: Thursday, September 4 at 1:30 pm PT/ 4:30 pm ET
Location: Boston, MA
Webcast Link: Click here
Lake Street Best Ideas Growth (BIG9) Conference
Format: 1×1 meetings
Date: Thursday, September 11
Location: New York, NY
A live and archived webcast of the fireside chat will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
[email protected]
